- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Canon Medical's AI-Powered Large-Bore CT
Aquilion system offers industry’s largest bore and widest field-of-view, potentially augmenting radiation therapy planning.
Canon Medical Systems received clearance from the U.S. Food & Drug Administration (FDA) Thursday for its Aquilion™ Exceed LB CT system that is designed to improve the planning and delivery of radiation therapy.
As an artificial intelligence-powered system, company officials said, Aquilion is intended to facilitate workflow while maintaining image quality and reproducibility.
Aquilion Exceed LB CT system. Credit: Canon Medical Systems USA, Inc.
“The Aquilion Exceed LB was designed to push the boundaries of traditional simulation,” said Erin Angel, CT business unit managing director for Canon Medical. “Deep learning reconstruction will give radiation oncology teams the confidence they need for accurate and precise planning across patients.”
Based on company details, Aquilion offers several benefits:
- 90-cm bore (industry’s largest bore opening)
- 90-cm extended-to-edge field-of-view reconstruction
- 4-cm wide detector coverage
- AI-powered contouring, using Canon Medical’s Advanced Intelligent Clear-IQ Engine (AiCE) deep learning reconstruction (DLR) technology
- Flexibility for handling bariatric patients, challenging patient positioning
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
